US 12,441,708 B2
Cereblon ligands and bifunctional compounds comprising the same
Andrew P. Crew, Chester, CT (US); Michael Berlin, Flemington, NJ (US); Keith R. Hornberger, Southbury, CT (US); Lawrence B. Snyder, Killingworth, CT (US); Jing Wang, Milford, CT (US); Yimin Qian, Plainsboro, NJ (US); Hanqing Dong, Madison, CT (US); and Kurt Zimmermann, Durham, CT (US)
Assigned to Arvinas Operations, Inc., New Haven, CT (US)
Filed by Arvinas Operations, Inc., New Haven, CT (US)
Filed on Dec. 12, 2022, as Appl. No. 18/079,790.
Application 18/079,790 is a continuation of application No. 15/885,671, filed on Jan. 31, 2018, abandoned.
Claims priority of provisional application 62/452,972, filed on Jan. 31, 2017.
Prior Publication US 2023/0183209 A1, Jun. 15, 2023
Int. Cl. C07D 401/14 (2006.01); A61P 35/02 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 495/14 (2006.01); C07D 498/04 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 35/02 (2018.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 495/14 (2013.01); C07D 498/04 (2013.01)] 20 Claims
 
1. A compound having the chemical structure:
CLM-L-PTM,
or a pharmaceutically acceptable salt thereof,
wherein the L is a chemical linking moiety covalently linking the CLM and the PTM, and wherein:
the PTM is

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein R designates the site of attachment to L; and
the CLM is selected from the group consisting of:

OG Complex Work Unit Chemistry
wherein
R3 is H, C1-C3 alkyl, or C1-C3 alkoxyl;
R4 is H or C1-C3 alkyl;
R5 is H or C1-C3 alkyl;
Q1, Q2, Q3, and Q4 are each independently a carbon substituted with a R′;
R′ is H, halogen, C1-C3 alkyl, or C1-C3 alkoxyl; and
Q5 is N; wherein the CLM is covalently joined to L via R3, R4, R5, R′, Q1, Q2, Q3, or Q4.